Summary

Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy condition characterized by an association of arthritis and psoriasis that can lead to progressive joint damage, disability, and reduced life expectancy [Rheumatol 2003;42:1460—8]. Using data from the 54 week IMPACT 2 trial data, this article assesses the effect of IFX 5mg/kg compared with a placebo on structural damage in 200 PsA patients.